I would very much agree. From a clinical trial point of view, I think the importance of having this regulatory framework is that until now many of our patients didn't get early access to clinical trials because we didn't have a designation for an orphan drug so we weren't talking with Canadians at the same time. It meant that patients and clinicians didn't benefit from it.
The other thing I think, as Mr. Lee is saying, is that it's very important that lots of new flexible frameworks are being designed internationally, specifically for rare diseases. Quite frankly we are also part of developing and designing those clinical trials so that we can take advantage of small patient populations but also ensure that we've got the right balance of benefits and risks.
Right now, where we sit, I think we're going to be able to make sure that we have more patients involved and certainly better access to early treatments.